Merck Granted Label Expansion by FDA for Keytruda
Keytruda, Merck's checkpoint inhibitor, has been granted label expansion by the U.S. Food and Drug Administration (FDA) for first-line treatment for patients diagnosed with, regardless of PD-L1 expression, locally advanced or metastatic gastroesophageal or esophageal...
FDA Grants EUA to Beckman Coulter’s COVID-19 Antibody Test
The U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to a COVID-19 antibody test created by Beckman Coulter. The antibody test measures the level of antibodies in a patient in response to COVID-19 to provide both a qualitative as well...
Study Shows AstraZeneca Vaccine Ineffective Against South African Variant
The New England Journal of Medicine published results from a study to test AstraZeneca's vaccine's efficacy for the South African variant of COVID-19. The clinical study was conducted in South Africa with 1,467 participants, of which 2.5% developed mild-to-moderate...
FDA Provides Smooth Pathway for COVID-19 Screening Tests
The U.S. Food and Drug Administration (FDA) is providing further guidance and a smoother path for COVID-19 screening tests, specifically for asymptomatic patients. Part of this process includes the release of a fact sheet for those interested in organizing screening...
EMA Offers Guidance on Labeling for COVID-19 Therapeutics
The European Medicines Agency (EMA) offered guidance on labeling requirements for COVID-19 therapeutics as a follow up on their guidance from last year that offered labeling requirement flexibilities on COVID-19 vaccinations. According to the EMA, the product's...
FDA Grants Approval for Medtronic’s Labeling of Intellis™ Platform
The U.S. Food and Drug Administration (FDA) granted approval for revised commercial labeling of Medtronic's Intellis™ Platform with Differential Target Multiplexed (DTM™). The platform is meant to treat chronic and intractable leg and back pain. Charlie Covert, VP and...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com